Magdeburg, Germany
eversyn is a German startup founded in 2022 with the slogan "Making high-value glycans mainstream." The company is a spin-off from the Max Planck Institute Magdeburg and is run, founded, and supported by current and former Max Planck scientists and business professionals. eversyn's proprietary technology focuses on the efficient use of novel, GMO-free biocatalytic cascades. The company has engineered pathways to produce nucleotide sugars by orders of magnitude cheaper than current production costs. Additionally, eversyn is working on engineering biocatalysts to produce human milk oligosaccharides and tailor the glycosylation of therapeutic proteins.
eversyn operates in the Biopharma, Biotechnology, and Nutrition industries and is headquartered in Germany. The company received a Seed Round investment on 01 January 2024, but the specific investors for this round are not disclosed.
